Relative effectiveness of sunitinib versus everolimus in advanced pancreatic neuroendocrine tumors: an updated matching-adjusted indirect comparison.

2.50
Hdl Handle:
http://hdl.handle.net/10541/621263
Title:
Relative effectiveness of sunitinib versus everolimus in advanced pancreatic neuroendocrine tumors: an updated matching-adjusted indirect comparison.
Authors:
Ishak, K; Rael, M; Hicks, M; Mittal, S; Eatock, M; Valle, Juan W ( 0000-0002-1999-0863 )
Abstract:
A matching-adjusted indirect comparison (MAIC) of sunitinib and everolimus has been previously reported based on the RADIANT-3 everolimus trial. We performed an analysis using updated overall survival (OS) data based on sunitinib's trial (A6181111).
Affiliation:
Evidera, Inc., Montreal, Canada
Citation:
Relative effectiveness of sunitinib versus everolimus in advanced pancreatic neuroendocrine tumors: an updated matching-adjusted indirect comparison. 2018, J Comp Eff Res
Journal:
Journal of Comparative Effectiveness Research
Issue Date:
31-Aug-2018
URI:
http://hdl.handle.net/10541/621263
DOI:
10.2217/cer-2018-0020
PubMed ID:
30168349
Type:
Article
Language:
en
ISSN:
2042-6313
Appears in Collections:
All Christie Publications

Full metadata record

DC FieldValue Language
dc.contributor.authorIshak, Ken
dc.contributor.authorRael, Men
dc.contributor.authorHicks, Men
dc.contributor.authorMittal, Sen
dc.contributor.authorEatock, Men
dc.contributor.authorValle, Juan Wen
dc.date.accessioned2018-09-30T15:30:41Z-
dc.date.available2018-09-30T15:30:41Z-
dc.date.issued2018-08-31-
dc.identifier.citationRelative effectiveness of sunitinib versus everolimus in advanced pancreatic neuroendocrine tumors: an updated matching-adjusted indirect comparison. 2018, J Comp Eff Resen
dc.identifier.issn2042-6313-
dc.identifier.pmid30168349-
dc.identifier.doi10.2217/cer-2018-0020-
dc.identifier.urihttp://hdl.handle.net/10541/621263-
dc.description.abstractA matching-adjusted indirect comparison (MAIC) of sunitinib and everolimus has been previously reported based on the RADIANT-3 everolimus trial. We performed an analysis using updated overall survival (OS) data based on sunitinib's trial (A6181111).en
dc.language.isoenen
dc.rightsArchived with thanks to Journal of comparative effectiveness researchen
dc.titleRelative effectiveness of sunitinib versus everolimus in advanced pancreatic neuroendocrine tumors: an updated matching-adjusted indirect comparison.en
dc.typeArticleen
dc.contributor.departmentEvidera, Inc., Montreal, Canadaen
dc.identifier.journalJournal of Comparative Effectiveness Researchen

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.